Amicus Therapeutics, Inc. (FOLD) — Analyst outlook / Analyst consensus target is. Based on 24 analyst ratings, the consensus is bullish — 16 Buy, 7 Hold, 1 Sell.
The consensus price target is $14.50, representing an upside of 0.3% from the current price $14.46.
Analysts estimate Earnings Per Share (EPS) of $-0.20 and revenue of $0.53B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.18 vs est $-0.20 (beat +11.7%). 2025: actual $-0.09 vs est $-0.01 (missed -515.3%). Analyst accuracy: 52%.
FOLD Stock — 12-Month Price Forecast
$14.50
▲ +0.28% Upside
Average Price Target
Based on 24 Wall Street analysts offering 12-month price targets for Amicus Therapeutics, Inc., the price target is $14.50.
The average price target represents a +0.28% change from the last price of $14.46.
FOLD Analyst Ratings
Buy
Based on 24 analysts giving stock ratings to Amicus Therapeutics, Inc. in the past 3 months
EPS Estimates — FOLD
52%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.18
vs Est –$0.20
▲ 13.2% off
2025
Actual –$0.09
vs Est –$0.01
▼ 83.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — FOLD
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.528B
vs Est $0.527B
▲ 0.2% off
2025
Actual $0.634B
vs Est $0.630B
▲ 0.7% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
